The Efficacy of SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction

Micrigoo Shimrt^*
*Correspondence: Micrigoo Shimrt, Department of Cardiology, University of Toronto, 27 King’s College Cir, Toronto, ON M5S 1A1, Canada, Email:

Introduction

Sodium-glucose co-transporter 2 inhibitors, primarily used for diabetes management, have shown promising results in patients with HFrEF. This randomized controlled trial demonstrated that SGLT2 inhibitors significantly reduce hospitalization rates and mortality in HFrEF patients, suggesting a potential new standard of care for this condition. Heart failure with reduced ejection fraction remains a significant global health challenge, affecting millions of individuals and leading to considerable morbidity and mortality. In recent years, Sodium-Glucose Co-Transporter 2 inhibitors, originally developed for diabetes management, have emerged as a promising therapeutic option for HFrEF. This article explores the efficacy of SGLT2 inhibitors in the treatment of HFrEF, highlighting their mechanisms of action, clinical trial outcomes, and their role in contemporary heart failure management.

HFrEF, characterized by a left ventricular ejection fraction of 40% or less, signifies impaired cardiac output due to weakened heart muscle contraction. Traditional treatment strategies have focused on symptom relief, improving quality of life, and reducing hospitalization and mortality rates. These strategies include the use of ACE inhibitors, beta-blockers, andmineralocorticoid receptor antagonists. Despite these therapies, many patients continue to experience symptomatic heart failure, indicating the need for additional treatment options [1-3].

SGLT2 inhibitors, such as empagliflozin, dapagliflozin, and canagliflozin, function by blocking the SGLT2 protein in the renal proximal tubules, leading to increased glucose excretion through urine. This mechanism, while primarily targeting hyperglycemia in diabetic patients, has shown unexpected cardiovascular benefits. The cardiovascular effects of SGLT2 inhibitors extend beyond glucose control and include diuresis and natriuresis, which reduce preload and afterload on the heart. Additionally, these inhibitors promote favorable hemodynamic effects, improve myocardial energetics, and reduce cardiac remodeling and fibrosis. The result is an overall improvement in heart function and a reduction in heart failure-related events.

Description

Dapagliflozin significantly reduced the risk of cardiovascular death or worsening heart failure by 26% compared to placebo, regardless of diabetic status. This trial was pivotal in establishing dapagliflozin as a viable treatment for HFrEF. Empagliflozin led to a 25% reduction in the combined risk of cardiovascular death or hospitalization for worsening heart failure. The trial underscored empagliflozin's benefit across various subgroups of HFrEF patients. Over 10,000 patients with type 2 diabetes at high cardiovascular risk. Although not focused exclusively on HFrEF, canagliflozin showed a significant reduction in heart failure hospitalization, suggesting its potential utility in heart failure management.

Integration into heart failure management involves incorporating various medical, technological, and patient-centered approaches to optimize treatment outcomes and improve the quality of life for patients. Specialized in diagnosing and treating heart conditions. Manage overall health and coordinate care. Provide day-to-day care, education, and support. Ensure appropriate medication management and adherence. Offer dietary advice to manage symptoms and improve health. Design exercise programs to enhance physical fitness and reduce symptoms. Address psychosocial issues and connect patients with community resources.

Reduce strain on the heart by relaxing blood vessels. Decrease heart rate and blood pressure. Help eliminate excess fluid to relieve symptoms. Prevent fluid retention. Newer class showing promise in reducing HF hospitalizations and cardiovascular death. Low-sodium diet to prevent fluid retention; balanced diet to support overall health. Regular physical activity tailored to the patient’s capabilities to improve cardiovascular health. Reducing risk factors associated with worsening HF. Teaching patients to recognize signs of exacerbation such as weight gain, swelling, or increased shortness of breath.

Devices like pacemakers and defibrillators to manage arrhythmias. Use of wearable devices and apps to track vital signs (e.g., heart rate, blood pressure) and symptoms, allowing for real-time adjustments in care. Virtual visits to ensure continuous care and support, especially beneficial for patients with mobility issues or living in remote areas. Structured follow-up plans to prevent readmissions, including early outpatient appointments and home health visits. Systems to ensure that all healthcare providers are informed about the patient’s condition and treatment plan, reducing the risk of errors and duplications [4,5].

Focuses on relieving symptoms, improving quality of life, and providing psychological and spiritual support. Ensuring patients’ wishes are respected through living wills and durable powers of attorney for healthcare. Identifying specific genetic markers that might influence treatment response. Using biomarkers like NT-proBNP to guide treatment decisions and monitor disease progression. Providing emotional support and coping strategies. Recognizing and treating mental health issues that often accompany chronic illness. Ensuring comprehensive and accessible patient records. Using data to identify trends, predict outcomes, and personalize care plans. Participation in trials to explore new treatments and interventions. Developing new drugs, devices, and techniques to improve outcomes.

The compelling evidence from these trials has led to the inclusion of SGLT2 inhibitors in heart failure management guidelines. The 2021 European Society of Cardiology and the 2022 American College of Cardiology /American Heart Association heart failure guidelines recommend SGLT2 inhibitors as a standard treatment option for patients with HFrEF, regardless of diabetes status. These recommendations mark a paradigm shift in heart failure therapy, recognizing the broad cardiovascular benefits of SGLT2 inhibitors.

Conclusion

SGLT2 inhibitors have revolutionized the management of HFrEF, offering significant reductions in heart failure-related morbidity and mortality. Their unique mechanisms, combined with robust clinical trial evidence, support their integration into standard heart failure treatment regimens. As research continues to evolve, SGLT2 inhibitors are poised to play an increasingly critical role in improving outcomes for patients with HFrEF, heralding a new era in heart failure therapeutics.

Acknowledgement

None.

Conflict of Interest

Authors declare no conflict of interest.

References

1. Zhao, Zinan, Pengfei Jin, Yatong Zhang and Xin Hu, et al. "SGLT2 inhibitors in diabetic patients with cardiovascular disease or at high cardiovascular risk: A systematic review and meta-analysis of randomized controlled trials." Front Cardiovasc Med 9 (2022): 826684.

   Google Scholar, Crossref, Indexed at

2. Hou, Yi-Chou, Cai-Mei Zheng, Tzung-Hai Yen and Kuo-Cheng Lu. "Molecular mechanisms of SGLT2 inhibitor on cardiorenal protection. Int J Mol Sci 21 (2020): 7833.

   Google Scholar, Crossref, Indexed at

3. Durak, Aysegul, Yusuf Olgar, Sinan Degirmenci and Erman Akkus, et al. "A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats." Cardiovasc Diabetol 17 (2018): 1-17.

   Google Scholar, Crossref, Indexed at

4. Mahmood, Syed S., Daniel Levy, Ramachandran S. Vasan, and Thomas J. Wang. "The Framingham Heart Study and the epidemiology of cardiovascular disease: A historical perspective." Lancet 383 (2014): 999-1008. 

   Google Scholar, Crossref, Indexed at

5. Mattar, Ahmed, David Carlston, Glen Sariol, and Tongle Yu, et al. "The prevalence of obesity documentation in primary care electronic medical records." App Clin Inf 26 (2017): 67-79.

   Google Scholar, Crossref, Indexed at